+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents



Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents



Clinics in Perinatology 39(1): 149-164



The perinatal transition from fetal to extrauterine life requires a dramatic change in the circulatory pattern as the organ of gas exchange switches from the placenta to the lungs. Pulmonary hypertension can occur during early newborn life, and present as early respiratory failure or as a complication of more chronic diseases, such as bronchopulmonary dysplasia. The most effective pharmacotherapeutic strategies for infants with persistent pulmonary hypertension of the newborn are directed at selective reduction of pulmonary vascular resistance. This article discusses currently available therapies for pulmonary hypertension, their biologic rationales, and evidence for their clinical effectiveness.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055290902

Download citation: RISBibTeXText

PMID: 22341543

DOI: 10.1016/j.clp.2011.12.006


Related references

Sildenafil is a pulmonary vasodilator which augments and prolongs vasodilatation by inhaled nitric oxide in patients with pulmonary hypertension. Circulation 100(18 Suppl. ): I 240, 1999

Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. American Journal of Cardiology 90(6): 677-680, 2002

Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Circulation 105(20): 2398-2403, 2002

Management of postoperative pulmonary hypertensive crisis in children--indication and usefulness of inhaled nitric oxide therapy as a pulmonary vasodilator. Nihon Kyobu Geka Gakkai 44(12): 2123-2129, 1996

Inhaled nitric oxide in primary pulmonary hypertension The Perfect pulmonary vasodilator. Circulation 92(8 Suppl. ): I241, 1995

Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 83(6): 2038-2047, 1991

Selective pulmonary vasodilator effect of inhaled nitric oxide in a patient with pulmonary thromboembolism. Medicina Clinica 105(7): 261-263, 1995

Inhaled nitric oxide a selective pulmonary vasodilator reversing human hypoxic pulmonary vasoconstriction hpv. Circulation 84(4 Suppl. 2): II91, 1991

Inhaled nitric oxide a selective pulmonary vasodilator for the treatment of persistent pulmonary hypertension of the newborn pphn. Circulation 84(4 Suppl. 2): II321, 1991

Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension. American Journal of Physiology. Lung Cellular and Molecular Physiology 290(4): L723-L729, 2006

Stimulation of soluble guanylate cyclase attenuates acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide. FASEB Journal 18(4-5): Abst 688 14, 2004

Phosphodiesterase inhibition with dipyridamole augments and prolongs the pulmonary vasodilator response to inhaled nitric oxide in adults with chronic pulmonary hypertension. Circulation 98(17 Suppl. ): I614, 1998

Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease. American Journal of Cardiology 77(7): 532-535, 1996

Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 110(15): 2253-2259, 2004